One of them is silibinin A, a compound isolated from milk thistle seeds, which binds the active site of MMP9 and inhibits TPA (12-O-tetradecanoylphorbol-13-acetate)-induced MMP9 and COX-2 expression via inhibition of the Raf/MEK/ERK pathway in breast cancer cells [181]. This evidence concerns the gene MMP9 and breast carcinoma.